MCID: IMM136
MIFTS: 45

Immune System Disease

Categories: Immune diseases, Neuronal diseases

Aliases & Classifications for Immune System Disease

MalaCards integrated aliases for Immune System Disease:

Name: Immune System Disease 12 15 17
Abnormality of the Immune System 29
Immune System and Disorders 42
Immune System Diseases 71

Classifications:



External Ids:

Disease Ontology 12 DOID:2914
ICD9CM 34 279.9
ICD10 32 D89.9
UMLS 71 C0021053 C0041806

Summaries for Immune System Disease

MedlinePlus : 42 Your immune system is a complex network of cells, tissues, and organs that work together to defend against germs. It helps your body to recognize these "foreign" invaders. Then its job is to keep them out, or if it can't, to find and destroy them. If your immune system cannot do its job, the results can be serious. Disorders of the immune system include Allergy and asthma - immune responses to substances that are usually not harmful Immune deficiency diseases - disorders in which the immune system is missing one or more of its parts Autoimmune diseases - diseases causing your immune system to attack your own body's cells and tissues by mistake

MalaCards based summary : Immune System Disease, also known as abnormality of the immune system, is related to immune deficiency disease and lymphatic system disease, and has symptoms including pathological conditions, signs and symptoms An important gene associated with Immune System Disease is CCR6 (C-C Motif Chemokine Receptor 6), and among its related pathways/superpathways are MicroRNAs in cancer and Alzheimers Disease. The drugs Midazolam and Morphine have been mentioned in the context of this disorder. Affiliated tissues include immune system, t cells and b cells.

Disease Ontology : 12 A disease of anatomical entity that is located in the immune system.

Wikipedia : 74 The immune system is a host defense system comprising many biological structures and processes within an... more...

Related Diseases for Immune System Disease

Diseases related to Immune System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 313)
# Related Disease Score Top Affiliating Genes
1 immune deficiency disease 34.0 SERPINA3 IRF4 ICOSLG H2AC18 CCR6
2 lymphatic system disease 32.9 U2AF1 SERPINA3 MIR9-1 MIR34A MIR223 MIR21
3 bacterial infectious disease 31.0 SERPINA3 MIR155 ICOSLG H2AC18 CCR6
4 connective tissue disease 30.9 U2AF1 SERPINA3 MIR9-1 MIR34A MIR223 MIR21
5 dermatitis, atopic 30.8 SERPINA3 MIR155 MIR142 ICOSLG CCR6
6 periodontitis 30.4 SERPINA3 MIR21 MIR146A
7 complement component 3 deficiency, autosomal recessive 11.5
8 autoimmune disease 11.3
9 trichohepatoenteric syndrome 1 11.0
10 leukocyte disease 11.0 U2AF1 SERPINA3 MIR21 MIR199A1 MIR17 MIR155
11 skin disease 11.0 U2AF1 SERPINA3 MIR21 MIR199A1 MIR17 MIR155
12 integumentary system disease 11.0 U2AF1 SERPINA3 MIR9-1 MIR21 MIR199A1 MIR17
13 mature b-cell neoplasm 11.0 U2AF1 MIR9-1 MIR199A1 MIR17 MIR155 MIR142
14 myeloma, multiple 11.0 U2AF1 SERPINA3 MIR9-1 MIR21 MIR199A1 MIR17
15 leukemia, acute lymphoblastic 11.0 U2AF1 MIR9-1 MIR223 MIR21 MIR199A1 MIR17
16 upper respiratory tract disease 11.0 SERPINA3 MIR9-1 MIR21 MIR199A1 MIR17 MIR155
17 spinal disease 11.0 U2AF1 SERPINA3 MIR9-1 MIR223 MIR21 MIR199A1
18 bronchial disease 11.0 SERPINA3 MIR21 MIR17 MIR155 MIR142 MIR126
19 contractures, pterygia, and spondylocarpotarsal fusion syndrome 1a 11.0 U2AF1 SERPINA3 MIR9-1 MIR21 MIR199A1 MIR17
20 bone inflammation disease 11.0 SERPINA3 MIR34A MIR223 MIR21 MIR199A1 MIR17
21 bone marrow cancer 11.0 U2AF1 MIR9-1 MIR34A MIR21 MIR199A1 MIR17
22 mouth disease 11.0 SERPINA3 MIR9-1 MIR21 MIR199A1 MIR181A1 MIR17
23 ovary epithelial cancer 11.0 U2AF1 SERPINA3 MIR9-1 MIR21 MIR199A1 MIR17
24 lymphoma, non-hodgkin, familial 11.0 U2AF1 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1
25 malignant ovarian surface epithelial-stromal neoplasm 11.0 U2AF1 SERPINA3 MIR9-1 MIR21 MIR199A1 MIR17
26 cervix disease 11.0 MIR9-1 MIR34A MIR21 MIR199A1 MIR17 MIR15A
27 central nervous system cancer 11.0 U2AF1 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1
28 squamous cell carcinoma, head and neck 11.0 U2AF1 MIR9-1 MIR21 MIR199A1 MIR181A1 MIR17
29 autoimmune disease of musculoskeletal system 11.0 SERPINA3 MIR21 MIR155 MIR146A MIR142 MIR125A
30 lung cancer susceptibility 3 11.0 U2AF1 SERPINA3 MIR9-1 MIR21 MIR199A1 MIR17
31 lung cancer 11.0 U2AF1 SERPINA3 MIR9-1 MIR34A MIR223 MIR21
32 eye disease 11.0 U2AF1 SERPINA3 MIR9-1 MIR223 MIR21 MIR199A1
33 endocrine system disease 11.0 U2AF1 SERPINA3 MIR9-1 MIR21 MIR199A1 MIR181A1
34 nervous system disease 11.0 U2AF1 SERPINA3 MIR9-1 MIR34A MIR223 MIR21
35 uveal disease 11.0 U2AF1 SERPINA3 MIR9-1 MIR199A1 MIR142 MIR125A
36 cardiovascular system disease 11.0 SERPINA3 MIR9-1 MIR34A MIR223 MIR21 MIR199A1
37 overnutrition 11.0 SERPINA3 MIR34A MIR223 MIR21 MIR199A1 MIR181A1
38 renal cell carcinoma, nonpapillary 11.0 MIR9-1 MIR34A MIR21 MIR199A1 MIR17 MIR15A
39 breast disease 11.0 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1 MIR181A1
40 temporal arteritis 11.0
41 autoinflammation, panniculitis, and dermatosis syndrome 11.0
42 allergic hypersensitivity disease 11.0
43 herpes zoster 11.0
44 vasculitis syndromes of the central and peripheral nervous systems 11.0
45 primary bacterial infectious disease 11.0 SERPINA3 MIR223 MIR21 MIR155 MIR142 MIR125A
46 body mass index quantitative trait locus 11 11.0 SERPINA3 MIR34A MIR223 MIR21 MIR199A1 MIR181A1
47 autosomal genetic disease 11.0 U2AF1 SERPINA3 MIR9-1 MIR21 MIR199A1 MIR181A1
48 hematologic cancer 11.0 U2AF1 SERPINA3 MIR9-1 MIR34A MIR223 MIR21
49 glucose metabolism disease 11.0 SERPINA3 MIR9-1 MIR223 MIR21 MIR199A1 MIR181A1
50 uterine anomalies 11.0 U2AF1 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1

Graphical network of the top 20 diseases related to Immune System Disease:



Diseases related to Immune System Disease

Symptoms & Phenotypes for Immune System Disease

UMLS symptoms related to Immune System Disease:


pathological conditions, signs and symptoms

Drugs & Therapeutics for Immune System Disease

Drugs for Immune System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 268)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
2
Morphine Approved, Investigational Phase 4 57-27-2 5288826
3
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
4
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
5
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
6
Aminosalicylic Acid Approved Phase 4 65-49-6 4649
7
Hydroxychloroquine Approved Phase 4 118-42-3 3652
8
Azithromycin Approved Phase 4 83905-01-5 447043 55185
9
Adenosine Approved, Investigational Phase 4 58-61-7 60961
10
Treosulfan Investigational Phase 4 299-75-2 9296
11 Neurotransmitter Agents Phase 4
12 Immunoglobulin A Phase 4
13 Hypnotics and Sedatives Phase 4
14 Interferon-alpha Phase 4
15 Narcotics Phase 4
16 Anti-Anxiety Agents Phase 4
17 Anesthetics, General Phase 4
18 Psychotropic Drugs Phase 4
19 GABA Modulators Phase 4
20 Analgesics, Opioid Phase 4
21 Anesthetics, Intravenous Phase 4
22 Angiotensin II Type 1 Receptor Blockers Phase 4
23 Angiotensinogen Phase 4
24 Angiotensin Receptor Antagonists Phase 4
25 Antihypertensive Agents Phase 4
26 Giapreza Phase 4
27 Analgesics, Non-Narcotic Phase 4
28 Fibrinolytic Agents Phase 4
29 Cyclooxygenase Inhibitors Phase 4
30 Platelet Aggregation Inhibitors Phase 4
31 Analgesics Phase 4
32 Anti-Inflammatory Agents, Non-Steroidal Phase 4
33 Mesalamine Phase 4 89-57-6
34 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
35 Antiprotozoal Agents Phase 4
36 Antiparasitic Agents Phase 4
37 Antimalarials Phase 4
38 Anticoagulants Phase 4
39
Ritonavir Approved, Investigational Phase 3 155213-67-5 392622
40
Lopinavir Approved Phase 3 192725-17-0 92727
41
Lamivudine Approved, Investigational Phase 3 134678-17-4 60825
42
Zidovudine Approved Phase 3 30516-87-1 35370
43
Desloratadine Approved, Investigational Phase 3 100643-71-8 124087
44
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
45
Bortezomib Approved, Investigational Phase 3 179324-69-7 387447 93860
46
Fluticasone Approved, Experimental Phase 3 90566-53-3 62924
47 Benralizumab Approved, Investigational Phase 3 1044511-01-4
48
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
49
Mycophenolic acid Approved Phase 3 24280-93-1 446541
50
tannic acid Approved Phase 3 1401-55-4

Interventional clinical trials:

(show top 50) (show all 224)
# Name Status NCT ID Phase Drugs
1 Normal Oxygenation Maintenance in Intensive Care Unit: Randomized Controlled Trial Unknown status NCT01319643 Phase 4 Oxygen
2 A Randomised Controlled Trial of a Strategy of Switching to Boosted PI Monotherapy Versus Continuing Combination ART for the Long-term Management of HIV-1 Infected Patients Who Have Achieved Sustained Virological Suppression on HAART Unknown status NCT01230580 Phase 4 Protease Inhibitor;Standard-of-care Antiretroviral therapy
3 Effect of Midazolam on Inflammatory Response and Organ Function in Mechanically Ventilated Sepsis Patients With Different Immune Status. Unknown status NCT02135055 Phase 4 Midazolam;Morphine
4 Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy:a Single Center Prospective Randomized Controlled Study Unknown status NCT02765594 Phase 4 Hydroxychloroquine Sulfate;Valsartan
5 The Effect of Aspirin Desensitization on Patients With Aspirin-exacerbated Respiratory Diseases Completed NCT01867281 Phase 4 aspirin
6 A Phase 4, Multi-Center, Randomized, Open-Label Study to Evaluate the Effect of BENLYSTA™ (Belimumab; HGS1006) on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01597492 Phase 4
7 A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy Completed NCT01990534 Phase 4 Brentuximab vedotin
8 Mesalamine to Reduce T Cell Activation in HIV Infection Completed NCT01090102 Phase 4 Mesalamine (5-aminosalicylic acid, Apriso);Placebo
9 Use of Traditional Chinese Medicine (Ren Shen Yang Rong Tang) Against Microinflammation in Hemodialysis Patients: A Quasi-randomized Controlled Trial Completed NCT02053740 Phase 4 Add R-S-Y-R-T (500 mg 3 times per day) for 6 months;Routine western medicine
10 Effect of Hydroxychloroquine on Atrial Fibrillation Recurrence After Radiofrequency Catheter Ablation in Patients With Atrial Fibrillation Recruiting NCT03592823 Phase 4 Hydroxychloroquine Sulfate 200 Mg Tablet
11 Effects of Azithromycin Treatment on Anti-viral Immunity in Patients With Asthma and COPD - A Randomized Double-blind, Placebo-controlled Trial Recruiting NCT04319705 Phase 4 Azithromycin;Placebo oral tablet
12 Evaluation of Immune Response to Vaccines in Primary Immune Disorders Recruiting NCT00023504 Phase 4
13 Allogeneic Stem Cell Transplant for Children and Adolescents With Acute Lymoblastic Leukemia FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
14 Methodology Study to Investigate the Utility of Retroviral Insertion Site Analysis in Samples From Subjects Treated With Strimvelis™ Gene Therapy Not yet recruiting NCT03311074 Phase 4
15 A Randomized, Open-label Trial to Compare the Efficacy and Safety of Early Initiation of cART With or Without Autologous HIV-1 Specific Cytotoxic T Lymphocyte (CTL) Infusion in Treatment-Naïve Acute HIV-1 Infected Adults Unknown status NCT02231281 Phase 3 cART(TDF/AZT+3TC+LPV/r)
16 A Phase III, Multi-Center, Randomized, Parallel-Group, Placebo-Controlled and Double- Blind Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Perennial Allergic Rhinitis Completed NCT01918033 Phase 3 Desloratadine 5 mg;Placebo
17 A Phase III, Multicenter, Open-Label Long-Term Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Eczema/Dermatitis and Dermal Pruritus. Completed NCT01916980 Phase 3 Desloratadine 5 mg
18 A Phase III Multicentre, Parallel-group, Randomized, Placebo-controlled, Double-blind Clinical Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Chronic Urticaria. Completed NCT01916967 Phase 3 Desloratadine;Placebo
19 A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis Completed NCT03054428 Phase 3 Dupilumab;Placebo
20 A Phase III, Multicenter, Open-Label Study To Evaluate the Efficacy and Safety of GAMMAPLEX® in Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00504075 Phase 3
21 Effectiveness of Pentoxifylline in Attenuating Neurological Disease Associated With HTLV-1 and Negative Modulator of Pathological Immune Response. Completed NCT01472263 Phase 3 Pentoxifylline;Placebo
22 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE) Completed NCT01205438 Phase 3 LY2127399;Placebo every 2 weeks;Placebo every 4 weeks
23 A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE) Completed NCT01196091 Phase 3 LY2127399;Placebo every 2 weeks;Placebo every 4 weeks;Standard of Care
24 A Randomized, Double-blind, Parallel-group Comparative Bioequivalence Trial of MabionCD20® (Mabion SA) Compared to MabThera® (Rituximab, Roche) in Patients With Rheumatoid Arthritis Completed NCT02468791 Phase 3 Rituximab
25 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Safety and Efficacy Trial of LJP 394 in Systemic Lupus Erythematosus (SLE) Patients With a History of Renal Disease Completed NCT00035308 Phase 3 Abetimus sodium (LJP 394)
26 Advanced Magnetic Resonance Imaging Measures of Repair in Alemtuzumab Treated Patients Completed NCT01307332 Phase 3 MabCampath-1h
27 A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids With Mycophenolate Mofetil vs. Corticosteroids With Placebo as Initial Systemic Treatment of Acute Graft-Vs-Host-Disease (BMT CTN #0802) Completed NCT01002742 Phase 3 Mycophenolate Mofetil;Placebo
28 An International, Multicenter, Randomized, Double-Blind Study of Vorinostat (MK0683) or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma Completed NCT00773747 Phase 3 vorinostat;bortezomib;placebo to vorinostat
29 T-Cell Depletion in Unrelated Donor Marrow Transplantation Completed NCT00000591 Phase 3
30 A PHASE 3 RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 AND DUPILUMAB IN COMPARISON WITH PLACEBO IN ADULT SUBJECTS ON BACKGROUND TOPICAL THERAPY, WITH MODERATE TO SEVERE ATOPIC DERMATITIS Completed NCT03720470 Phase 3 PF-04965842 100 mg;PF-04965842 200 mg;Dupilumab;Oral Placebo;Injectable Placebo
31 Fluticasone Propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Two-Part, Randomized, Double-blind, Placebo-Controlled Study of APT-1011 in Adult and Adolescent Subjects With Eosinophilic Esophagitis Recruiting NCT04281108 Phase 3 APT-1011;Placebo oral tablet
32 Effect of Early Oral Colostrum Administration Versus Placebo on the Immune System in Premature Newborns Under 32 Weeks of Gestation: A Randomized Clinical Trial. Active, not recruiting NCT03578341 Phase 3
33 A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus. Active, not recruiting NCT02794285 Phase 3 Placebo
34 A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Active, not recruiting NCT02549170 Phase 3
35 A PHASE 3 RANDOMIZED WITHDRAWAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 IN SUBJECTS AGED 12 YEARS AND OVER, WITH MODERATE TO SEVERE ATOPIC DERMATITIS WITH THE OPTION OF RESCUE TREATMENT IN FLARING SUBJECTS Active, not recruiting NCT03627767 Phase 3 PF-04965842 100 mg;PF-04965842 200 mg;Placebo
36 A Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled, Phase 3b Study to Evaluate the Safety and Efficacy of Benralizumab 30 mg sc in Patients With Severe Asthma Uncontrolled on Standard of Care Treatment Active, not recruiting NCT03170271 Phase 3 Benralizumab (Medi-563);Placebo
37 A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE) (Illuminate-X) Terminated NCT01488708 Phase 3 LY2127399;Placebo
38 A 52-week, Multicenter, Randomized, Double-blind, Double-dummy, Parallel-group, Placebo-controlled Study of Fevipiprant Once Daily Plus Standard-of-care (SoC) for Reduction of Systemic Corticosteroids (Oral and Parenteral) Use in Patients With Severe Asthma Terminated NCT03629249 Phase 3 Placebo;QAW039 Dose 1;QAW039 Dose 2
39 In-vivo T-cell Depletion and Hematopoietic Stem Cell Transplantation for Life-Threatening Immune Deficiencies and Histiocytic Disorders Terminated NCT00176826 Phase 2, Phase 3 Myeloablative conditioning regimen
40 A Phase 3 Randomized,Open-Label Study of Ponatinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Terminated NCT01650805 Phase 3 ponatinib;imatinib (Gleevec/ Glivec)
41 SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring ASCT for Relapsed DLBCL Terminated NCT02366663 Phase 3 Carmustine;Etoposide;Cytarabine;Melphalan
42 Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus "Conventional Treatment" for Treating Steroid Resistant Acute Graft-versus Host Disease Terminated NCT02411084 Phase 3
43 A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of MSRD-100 in Subjects >=3 Months of Age With Atopic Dermatitis Withdrawn NCT02677636 Phase 3 MSRD-100;Vehicle
44 A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of MSRD-100 in Subjects >=3 Months of Age With Atopic Dermatitis Withdrawn NCT02677610 Phase 3 MSRD-100;Vehicle
45 Chronic Non-bacterial Osteomyelitis Treated With Pamidronate in a Randomised Placebo Controlled Trial Unknown status NCT02594878 Phase 2 Pamidronatdinatrium
46 The Effect of Subantimicrobial Dose Doxycycline in Mild Graves' Orbitopathy Unknown status NCT02203682 Phase 2 Doxycycline;placebo
47 Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia. Unknown status NCT01579110 Phase 2 levamisole;Prednisone
48 Multicenter Clinical Trial Evaluating the Immunological Response of Vaccination Against Infection by Human Papillomavirus (HPV) 6, 11, 16, 18 in Girls Receiving Immunosuppressive Therapy. Unknown status NCT01687192 Phase 2
49 Clinical Research of Gene Therapy for Refractory B-Cell Non-Hodgkin Lymphoma Using Autologous T Cells Expressing a Chimeric Antigen Receptor Specific to the CD19 Antigen Unknown status NCT02134262 Phase 1, Phase 2 Cyclophosphamide or Bendamustine
50 Extract Allergen From Betula Verrucosa. Test Sensitivity and Specificity of Diagnostic in Prick Test Preparation Completed NCT02527187 Phase 2

Search NIH Clinical Center for Immune System Disease

Genetic Tests for Immune System Disease

Genetic tests related to Immune System Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Immune System 29

Anatomical Context for Immune System Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Immune System Disease:

19
Immune System

MalaCards organs/tissues related to Immune System Disease:

40
T Cells, B Cells, Brain, Bone, Bone Marrow, Testes, Kidney

Publications for Immune System Disease

Articles related to Immune System Disease:

(show top 50) (show all 117)
# Title Authors PMID Year
1
How the COVID-19 Overcomes the Battle? An Approach to Virus Structure. 42
32361692 2020
2
Strengthening the Immune System and Reducing Inflammation and Oxidative Stress through Diet and Nutrition: Considerations during the COVID-19 Crisis. 42
32471251 2020
3
Prenatal development of human immunity. 42
32381715 2020
4
An integrated metabolism in vivo analysis and network pharmacology in UC rats reveal anti-ulcerative colitis effects from Sophora flavescens EtOAc extract. 61
32371325 2020
5
Molecular docking with Gaussian Boson Sampling. 61
32548251 2020
6
The Performance of Gene Expression Signature-Guided Drug-Disease Association in Different Categories of Drugs and Diseases. 61
32560162 2020
7
Development and physicochemical characterization of chitosan hydrochloride/sulfobutyl ether-β-cyclodextrin nanoparticles for cinnamaldehyde entrapment. 61
32189350 2020
8
Investigation of the Impacts of Antibiotic Exposure on the Diversity of the Gut Microbiota in Chicks. 61
32455745 2020
9
A review of the phytochemistry and pharmacological activities of Ephedra herb. 61
32451091 2020
10
The responses of the gut microbiota to MBL deficiency. 61
32330757 2020
11
DOHaD: a disease-oriented, epoch-making, British-originated theory with Hungarian roots 61
32323964 2020
12
When Behcet's disease meets Stanford type A aortic dissection, heart transplantation is a reliable treatment. 61
32309398 2020
13
[Clinical predictive value of short-term dynamic changes in platelet counts for prognosis of sepsis patients in intensive care unit: a retrospective cohort study in adults]. 61
32385993 2020
14
Sodium butyrate modulates gut microbiota and immune response in colorectal cancer liver metastatic mice. 61
32172331 2020
15
Effect of different seasons (spring vs summer) on the microbiota diversity in the feces of dairy cows. 61
31707493 2020
16
Bioinformatics analysis of gene and microRNA targets for fibromyalgia. 61
32083545 2020
17
Case report on a 32-year-old female with elevated serum creatinine levels and primary Sjögren's syndrome-chronic interstitial nephritis. 61
31772632 2019
18
Co-evaluation of interaction parameters of genomic and plasmid DNA for a new chromatographic medium. 61
31520707 2019
19
Prevalence of CCR5delta32 in Northeastern Iran. 61
31730458 2019
20
Analysis of Panax ginseng miRNAs and Their Target Prediction Based on High-Throughput Sequencing. 61
31434113 2019
21
Trehalose suppresses cadmium-activated Nrf2 signaling pathway to protect against spleen injury. 61
31195231 2019
22
A link between environmental pollution and civilization disorders: a mini review. 61
31141493 2019
23
The gastrointestinal fate of limonin and its effect on gut microbiota in mice. 61
31418448 2019
24
High-Throughput Sequencing Reveals the Gut Microbiome of the Bactrian Camel in Different Ages. 61
31030270 2019
25
Statistical analysis of disease-causing and neutral mutations in human membrane proteins. 61
30714211 2019
26
Medicinal plants of the Caatinga, northeastern Brazil: Ethnopharmacopeia (1980-1990) of the late professor Francisco José de Abreu Matos. 61
30885881 2019
27
Colitis-induced colorectal cancer and intestinal epithelial estrogen receptor beta impact gut microbiota diversity. 61
30515752 2019
28
Gut microbiota characterization and lipid metabolism disorder found in PCB77-treated female mice. 61
30935970 2019
29
Hsp70 interactions with membrane lipids regulate cellular functions in health and disease. 61
30710597 2019
30
Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma. 61
30885723 2019
31
Mathematical Models for Possible Roles of Oxytocin and Oxytocin Receptors in Autism. 61
31827587 2019
32
Distinct Gut Microbiota Composition and Functional Category in Children With Cerebral Palsy and Epilepsy. 61
31646147 2019
33
Muscular Tuberculosis: A New Case and a Review of the Literature. 61
31632334 2019
34
The Variation of Nasal Microbiota Caused by Low Levels of Gaseous Ammonia Exposure in Growing Pigs. 61
31156592 2019
35
Effects of Captivity and Season on the Gut Microbiota of the Brown Frog (Rana dybowskii). 61
31507549 2019
36
Epigenetic Modification Related to Acetylation of Histone and Methylation of DNA as a Key Player in Immunological Disorders. 61
31002589 2019
37
Computational comparison of two new fusion proteins for multiple sclerosis. 61
30271441 2018
38
Stiff person syndrome with elevated titers of antibodies against cardiolipin and β2 glycoprotein 1: a case report and literature review. 61
30179217 2018
39
Cinnamaldehyde protects VSMCs against ox-LDL-induced proliferation and migration through S arrest and inhibition of p38, JNK/MAPKs and NF-κB. 61
29777873 2018
40
Porcine cluster of differentiation (CD) markers 2018 update. 61
29518710 2018
41
Oxidative stress: role of physical exercise and antioxidant nutraceuticals in adulthood and aging. 61
29682215 2018
42
[Diffusion of Microorganism and Main Pathogenic Bacteria During Municipal Treated Wastewater Discharged into Sea]. 61
29965485 2018
43
Postmenopausal breast cancer and oestrogen associations with the IgA-coated and IgA-noncoated faecal microbiota. 61
29360814 2018
44
Protective Effects of Anti-IL17 on Acute Lung Injury Induced by LPS in Mice. 61
30337870 2018
45
Comparative transcriptome analysis of Eriocheir japonica sinensis response to environmental salinity. 61
30192896 2018
46
Research Techniques Made Simple: Murine Models of Human Psoriasis. 61
29273150 2018
47
The Protective Effects of Extra Virgin Olive Oil on Immune-mediated Inflammatory Responses. 61
29141575 2018
48
The vitamin D receptor and the etiology of RANTES/CCL-expressive fatty-degenerative osteolysis of the jawbone: an interface between osteoimmunology and bone metabolism. 61
29731660 2018
49
Integrated strategy of differentially expressed genes associated with ulcerative colitis. 61
28944823 2017
50
[Clinical applications of stem cells from human exfoliated deciduous teeth in stem cell therapy]. 61
29188652 2017

Variations for Immune System Disease

Expression for Immune System Disease

Search GEO for disease gene expression data for Immune System Disease.

Pathways for Immune System Disease

Pathways related to Immune System Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.93 MIR9-1 MIR34A MIR223 MIR21 MIR199A1 MIR181A1
2 11.63 MIR9-1 MIR21 MIR181A1 MIR125A
3 10.84 MIR9-1 MIR199A1 MIR181A1 MIR150
4 10.21 MIR150 MIR126

GO Terms for Immune System Disease

Cellular components related to Immune System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.81 SERPINA3 MIR9-1 MIR21 MIR15A MIR155 MIR146A
2 extracellular space GO:0005615 9.44 SERPINA3 MIR223 MIR21 MIR199A1 MIR181A1 MIR17
3 extracellular vesicle GO:1903561 9.43 MIR34A MIR21 MIR17 MIR15A MIR126 MIR125A

Biological processes related to Immune System Disease according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.03 MIR125A MIR146A MIR155 MIR21 MIR223 MIR34A
2 negative regulation of gene expression GO:0010629 9.97 MIR125A MIR146A MIR155 MIR17 MIR181A1 MIR21
3 positive regulation of inflammatory response GO:0050729 9.83 MIR126 MIR155 MIR21
4 negative regulation of NF-kappaB transcription factor activity GO:0032088 9.83 MIR155 MIR15A MIR21
5 cellular response to hypoxia GO:0071456 9.83 MIR126 MIR146A MIR155 MIR17 MIR34A
6 negative regulation of inflammatory response GO:0050728 9.8 MIR126 MIR142 MIR146A MIR155 MIR15A MIR181A1
7 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.77 MIR15A MIR223 MIR34A
8 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.77 MIR126 MIR146A MIR150
9 negative regulation of angiogenesis GO:0016525 9.77 MIR125A MIR146A MIR15A MIR21 MIR34A
10 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.76 MIR125A MIR146A MIR155
11 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.76 MIR146A MIR155 MIR15A MIR199A1
12 negative regulation of NIK/NF-kappaB signaling GO:1901223 9.75 MIR146A MIR21 MIR223
13 positive regulation of sprouting angiogenesis GO:1903672 9.74 MIR125A MIR126 MIR155
14 positive regulation of activated T cell proliferation GO:0042104 9.72 ICOSLG MIR155 MIR21
15 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.71 MIR126 MIR146A MIR21
16 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.7 MIR155 MIR17 MIR199A1
17 miRNA mediated inhibition of translation GO:0035278 9.7 MIR146A MIR155 MIR15A MIR17 MIR181A1 MIR21
18 positive regulation of connective tissue replacement GO:1905205 9.69 MIR155 MIR199A1 MIR34A
19 negative regulation of tyrosine phosphorylation of STAT protein GO:0042532 9.67 MIR125A MIR146A
20 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.66 MIR155 MIR17
21 negative regulation of cytokine-mediated signaling pathway GO:0001960 9.65 MIR125A MIR21
22 cellular response to oxidised low-density lipoprotein particle stimulus GO:0140052 9.65 MIR146A MIR155
23 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.65 MIR155 MIR17 MIR199A1
24 positive regulation of microglial cell activation GO:1903980 9.64 MIR142 MIR155
25 negative regulation of matrix metallopeptidase secretion GO:1904465 9.64 MIR146A MIR199A1
26 negative regulation of interleukin-8 production GO:0032717 9.63 MIR146A MIR155
27 positive regulation of metalloendopeptidase activity GO:1904685 9.63 MIR17 MIR21
28 negative regulation of regulatory T cell differentiation GO:0045590 9.62 MIR155 MIR21
29 negative regulation of vascular wound healing GO:0061044 9.62 MIR155 MIR34A
30 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.62 MIR15A MIR21 MIR223 MIR34A
31 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.61 MIR17 MIR21
32 negative regulation of necrotic cell death GO:0060547 9.61 MIR155 MIR223
33 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.58 MIR125A MIR146A MIR155
34 gene silencing by miRNA GO:0035195 9.47 MIR125A MIR126 MIR142 MIR146A MIR150 MIR155
35 negative regulation of vascular endothelial growth factor production GO:1904046 9.43 MIR125A MIR146A MIR15A MIR17 MIR199A1 MIR34A

Molecular functions related to Immune System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.47 MIR9-1 MIR34A MIR223 MIR21 MIR199A1 MIR181A1
2 mRNA 3'-UTR binding GO:0003730 9.13 MIR21 MIR146A MIR125A

Sources for Immune System Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....